声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向特宝生物提问："目前，中国医药海外BD如火如荼。请问派格宾有这样的可能 吗？" 针对上述提问，特宝生物回应称："您好！派格宾作为全球首个以乙肝临床治愈为治疗目标的药物，有 望助力更多乙肝患者实现更高的治疗目标，未来公司将根据经营情况进一步拓展国际业务。感谢您的关 注。" ...

经济观察网特宝生物近期公告显示，公司拟发行可转换公司债券募集资金总额不超过15.33亿元，用于 新药研发等项目。同时，公司2025年业绩快报显示营业收入36.96亿元，同比增长31.18%，归母净利润 10.38亿元，同比增长25.39%。 定增股票 业绩经营情况 公司于2026年2月10日晚间披露了2025年业绩快报，显示营业收入36.96亿元，同比增长31.18%，归母净 利润10.38亿元，同比增长25.39%。业绩增长主要受重点产品派格宾销售收入稳定增长及新产品益佩生 上市推动。 以上内容基于公开资料整理，不构成投资建议。 特宝生物于2026年1月26日晚间公告，拟发行可转换公司债券募集资金总额不超过15.33亿元，用于新药 研发项目、生物技术创新融合中心建设项目及创新药物生产改扩项目。这一计划旨在加码主业，提升研 发能力和产能。 ...

长效生物制剂龙头特宝生物(688278.SH)经营业绩再现稳健增长。 2月10日晚，特宝生物披露了2025年业绩快报。当年，公司实现的营业收入、归母净利润分别为36.96亿 元、10.38亿元，同比增速均超过20%，均创下历史新高。 特宝生物解释，公司重点产品销售收入稳定增长，新产品获批上市带来销售收入新增长点。 长江商报记者发现，2018年至2025年的八个年度，特宝生物的营收净利实现了连续八年增长。 与业绩增长相关联的是，特宝生物的经营现金流持续净流入。2025年前三季度，公司经营现金流净额为 4.71亿元，同比增长61.33%。 特宝生物重点聚焦乙肝临床治愈领域，截至2025年6月末，公司已经上市六个药品及一款电子笔式注射 器。 特宝生物的研发投入持续增加，2025年前三季度，公司研发投入为3.12亿元，同比增长38.67%。 特宝生物持续回报股东。2020年上市以来，公司已经连续五年分红，合计分红5.67亿元，为股权融资额 的1.5倍。 年度盈利首次突破10亿大关 特宝生物业绩延续双增的良好发展势头。 根据最新发布的业绩快报，2025年，特宝生物实现营业收入36.96亿元，同比增长31.18%；归母净 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all proposed resolutions were approved without any objections from shareholders [2][9]. Group 1: Meeting Details - The meeting took place on February 11, 2026, at the company's conference room located at 330 Wengjiao Road, Haicang New Industrial Zone, Xiamen [2]. - The meeting was convened by the board of directors and chaired by Mr. Sun Li, the chairman [2]. - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2]. Group 2: Attendance - All 9 current directors attended the meeting, along with the company secretary Ms. Yang Yiling and some senior management personnel [3]. Group 3: Resolutions Reviewed - The following resolutions were passed: - Approval for the company to issue convertible bonds to unspecified investors [4]. - Approval of the bond issuance plan, including types of securities, issuance scale, face value, issuance price, bond term, interest rate, repayment terms, conversion period, and pricing adjustments [4][5][6][7]. - Approval of the use of raised funds, management of funds, and related guarantees [7]. - Approval of the feasibility analysis report for the use of raised funds and the dilution of immediate returns with measures to compensate [8]. - Approval of the company's dividend return plan for the next three years (2026-2028) [8]. - Authorization for the board of directors to handle all matters related to the issuance of convertible bonds [8]. Group 4: Voting and Legal Verification - All resolutions were special resolutions and were passed with more than two-thirds of the voting rights held by attending shareholders [9]. - The meeting was witnessed by lawyers from Shanghai Jintiancheng (Shenzhen) Law Firm, who confirmed that the meeting complied with legal and procedural requirements [9].

证券代码：688278 证券简称：特宝生物 公告编号：2026-012 （一） 股东会召开的时间：2026 年 2 月 11 日 （二） 股东会召开的地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 229,173,676 | | 普通股股东所持有表决权数量 | 229,173,676 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 56.14 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.14 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 厦门特宝生物工程股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ...

上海市锦天城（深圳）律师事务所 关于 厦门特宝生物工程股份有限公司 2026 年第一次临时股东会之 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于厦门特宝生物工程股份有限公司 2026 年第一次临时股东会之 法律意见书 致：厦门特宝生物工程股份有限公司 根据厦门特宝生物工程股份有限公司（以下简称"贵公司"或者"公司"）的委托，并 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）等法律、行政法规以及《厦门特宝生物工程股份有限公司章程》 （以下简称"《公司章程》"）、《厦门特宝生物工程股份有限公司股东会议事规则》（以 下简称"《股东会议事规则》"）的规定，上海市锦天城（深圳）律师事务所（以下简称"本 所"）指派律师见证公司 2026 年第一次临时股东会（以下简称"本次股东会"），现就公 司本次股东会召开的有关事宜出具本法律意见书。 本所同意将本法律意见书随贵公司本次股东会的 ...

Core Viewpoint - The company reported significant growth in both revenue and net profit for the year 2025, driven by stable sales of key products and the introduction of new products [1] Financial Performance - The company achieved an annual revenue of 3.696 billion yuan, representing a year-on-year increase of 31.18% [1] - The net profit attributable to shareholders reached 1.038 billion yuan, reflecting a year-on-year growth of 25.39% [1] Key Growth Drivers - The substantial revenue growth is primarily attributed to the stable sales of the key product, Paigebin [1] - The approval and market launch of the new product, Yipeisheng, provided a new revenue growth point for the company [1]

Core Viewpoint - The company, Xiamen Te Bao Biological Engineering Co., Ltd., reported steady growth in its 2025 annual performance, with significant increases in revenue and profit metrics, leading to a rise in stock price and market capitalization [1][7]. Financial Performance - Total operating revenue for 2025 reached 3.696 billion RMB, a year-on-year increase of 31.18% from 2.817 billion RMB [3][4]. - Operating profit was 1.254 billion RMB, up 29.14% from 971 million RMB in the previous year [3][4]. - Total profit amounted to 1.178 billion RMB, reflecting a 26.56% increase from 931 million RMB [3][4]. - Net profit attributable to shareholders was 1.038 billion RMB, a 25.39% rise from 828 million RMB [3][4]. - Basic earnings per share were 2.55 RMB, up 25.62% from 2.03 RMB [3][4]. Asset Status - Total assets at the end of the reporting period were 4.369 billion RMB, a 43.21% increase from 3.050 billion RMB at the beginning of the period [3][4]. - Shareholders' equity attributable to the parent company was 3.456 billion RMB, up 35.36% from 2.553 billion RMB [3][4]. - The net asset value per share attributable to the parent company was 8.47 RMB, a 34.87% increase from 6.28 RMB [3][4]. Growth Drivers - The growth in performance is attributed to the dual drivers of core products and new product launches, particularly the approval of Peginterferon α-2b injection for chronic hepatitis B and the new product Yipeisheng [5][13]. - Peginterferon has shown significant clinical efficacy, with a cure rate exceeding 30% and a maintenance rate of 90% over two years [5][13]. - Yipeisheng has been included in the national medical insurance directory, contributing to new revenue growth [5][13]. Market Outlook - Guojin Securities highlighted the company's leadership in PEG long-acting drugs, with three approved products, and expects accelerated growth in 2026 as new indications and insurance coverage take effect [6][15]. - The company is also expanding into innovative fields such as small nucleic acid drugs and antibody drugs, with plans to raise 1.533 billion RMB for new drug development [6][15]. - Profit forecasts for 2025-2027 predict net profits of 1.036 billion RMB, 1.402 billion RMB, and 1.769 billion RMB, representing growth rates of 25.2%, 35.3%, and 26.1% respectively [6][15].

（特宝生物公告） 报告期内，公司整体经营及财务状况稳健，主要得益于重点产品派格宾销售收入的稳定增长以及新产品 益佩生的上市带来的新销售增长点。尽管新产品上市初期市场拓展及核心产品覆盖提升导致相关费用增 加，但公司创新成果的快速临床应用推动了整体经营的稳健增长。 近日，特宝生物发布公告称，2025年度公司实现营业总收入36.96亿元，同比增长31.18%；归母净利润 为10.38亿元，同比增长25.39%。 ...

Core Insights - The news highlights significant corporate announcements and performance reports from various companies, indicating potential investment opportunities and market movements. Group 1: Corporate Announcements - Ge Weidong invested 1 billion yuan to subscribe for shares in Jianghuai Automobile's private placement, acquiring approximately 20.05 million shares at a price of 49.88 yuan per share, contributing to a total fundraising of about 3.5 billion yuan from eight investors [3][4] - *ST Cube completed its suspension review and will resume trading on February 11, 2026, after confirming no undisclosed significant matters related to the company [2] - Yunnan Baiyao plans to invest 137 million yuan in a second phase project for oral liquid production to meet growing market demand [11] Group 2: Performance Reports - Semiconductor manufacturer SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, reaching 1.223 billion yuan, driven by increased wafer sales and improved capacity utilization [5] - Special Biological Company reported a net profit of 1.038 billion yuan for 2025, reflecting a 25.39% increase year-on-year, attributed to stable sales of key products and new product approvals [6] - New Zobang achieved a net profit of 1.098 billion yuan in 2025, marking a 16.56% increase compared to the previous year [6] Group 3: Fundraising and Restructuring - New Han New Materials plans to raise up to 1 billion yuan through a private placement to fund projects related to high-performance resins and composite materials [8] - Chutian Long intends to raise up to 760 million yuan for the development of innovative safety products and digital operations [8] - Yi Yi Co. decided to terminate its plan to acquire 100% equity of a pet food company due to changes in the target company's operational conditions [8] Group 4: Major Contracts and Investments - Yunjiji Group signed an EPC contract worth 1.331 billion yuan for a cement production line and power station in Zimbabwe, representing 86.66% of the company's audited revenue for 2024 [9] - Solar Energy's subsidiary plans to acquire 100% of Jinhua Windling for 527 million yuan, enhancing its position in the solar power industry [9] - Yutong Technology intends to acquire 51% of Huayan Technology for 448.8 million yuan, which will become a subsidiary post-transaction [9]